SomanathanS, CalcedoR, WilsonJM. Adenovirus-antibody complexes contributed to lethal systemic inflammation in a gene therapy trial. Mol Ther, 2020; 28:784–793.
2.
YangY, NunesFA, BerencsiK, et al.Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci U S A, 1994; 91:4407–4411.
3.
YangY, ErtlHC, WilsonJM. MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses. Immunity, 1994; 1:433–442.
4.
GaoGP, YangY, WilsonJM. Biology of adenovirus vectors with E1 and E4 deletions for liver-directed gene therapy. J Virol, 1996; 70:8934–8943.
5.
GaoG, WangQ, DaiZ, et al.Adenovirus-based vaccines generate cytotoxic T lymphocytes to epitopes of NS1 from dengue virus that are present in all major serotypes. Hum Gene Ther, 2008; 19:927–936.
6.
MercadoNB, ZahnR, WegmannF, et al.Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. Nature, 2020; 586:583–588.
7.
EwerKJ, BarrettJR, Belij-RammerstorferS, et al.T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial. Nat Med, 2021; 27:270–278.
8.
AlterG, YuJ, LiuJ, et al. Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans. Nature 2021 [Epub ahead of print]; DOI: 10.1038/s41586-021-03681-2.
